PapersFlow Research Brief
Tuberculosis Research and Epidemiology
Research Guide
What is Tuberculosis Research and Epidemiology?
Tuberculosis research and epidemiology is the scientific study of Mycobacterium tuberculosis biology, transmission, clinical management, and population-level disease burden to inform prevention, diagnosis, treatment, and control strategies.
The Tuberculosis Research and Epidemiology literature spans 229,032 works and includes molecular genetics, diagnostics, treatment regimens, immune response, drug resistance, and population surveillance across settings. "Global Burden of Tuberculosis" (1999) quantified global incident and prevalent TB using WHO surveillance, including an estimate of 7.96 million new TB cases in 1997 (range 6.3–11.1 million) and 16.2 million existing cases (range 12.1–22.5 million). "Global tuberculosis report 2025" (2025) reported 10.7 million people fell ill with TB in 2024 and 1.23 million TB deaths in 2024, providing a current benchmark for monitoring progress.
Topic Hierarchy
Research Sub-Topics
Mycobacterium tuberculosis Genomics
This sub-topic focuses on sequencing the Mtb genome, identifying virulence factors, and genetic diversity across strains. Researchers develop tools for phylogenetic analysis and evolutionary studies.
Tuberculosis Drug Resistance Mechanisms
This sub-topic examines molecular basis of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), including efflux pumps and mutations. Studies evaluate resistance evolution and surveillance strategies.
Host Immune Response to Tuberculosis
This sub-topic investigates innate and adaptive immunity against Mtb, granuloma formation, and immune evasion tactics. Researchers explore cytokine profiles, T-cell responses, and latency mechanisms.
Tuberculosis Vaccine Development
This sub-topic covers BCG vaccine limitations, novel subunit vaccines, and viral-vectored candidates like M72/AS01E. Clinical trials and correlates of protection are key research foci.
Global Tuberculosis Epidemiology
This sub-topic analyzes incidence trends, transmission dynamics, and risk factors using WHO surveillance data and modeling. Researchers study HIV-TB coinfection and social determinants.
Why It Matters
Tuberculosis research and epidemiology directly guides clinical risk management, diagnostic strategy, and public-health prioritization by linking mechanistic understanding to measurable population outcomes. For example, Keane et al. (2001) in "Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent" reported that active TB may develop soon after initiation of infliximab and explicitly recommended screening for latent TB infection or disease before prescribing, a concrete practice change relevant to rheumatology and gastroenterology services using TNF-α inhibitors. At the population level, Dye et al. (1999) in "Global Burden of Tuberculosis" provided surveillance-based estimates (e.g., 7.96 million new cases in 1997; 44% smear-positive infectious pulmonary disease), which are the kinds of metrics used to set priorities for case-finding and transmission reduction. More recently, "global-tb-report-2025_factsheet.pdf" (2025) and "Tuberculosis: Global deaths decline for first time since pandemic" (2025) reported 10.7 million people fell ill with TB in 2024 (a 1% reduction from 10.8 million in 2023) and 1.23 million TB deaths in 2024, while "GTBreport2024_top findings and messages_English" (2025) quantified financing gaps (US$5.9 billion for TB services in 2024 and US$1.2 billion for TB research in 2023, stated as 27% and 24% of the respective global targets), linking epidemiologic trends to operational capacity for diagnostics, treatment, and research.
Reading Guide
Where to Start
Start with Dye et al. (1999), "Global Burden of Tuberculosis", because it provides concrete global incidence/prevalence estimates and explicitly separates infectious pulmonary (smear-positive) disease, giving essential epidemiologic framing for subsequent mechanistic and diagnostic papers.
Key Papers Explained
Dye et al. (1999) in "Global Burden of Tuberculosis" establishes population-level burden metrics that motivate biological and operational research. Cole et al. (1998) in "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" provides the genomic basis for mechanistic hypotheses and target discovery, which Sassetti et al. (2003) in "Genes required for mycobacterial growth defined by high density mutagenesis" advances by experimentally defining growth-required genes relevant to drug targeting. Kamerbeek et al. (1997) in "Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology" connects laboratory methods to transmission monitoring needs central to epidemiology. Keane et al. (2001) in "Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent" demonstrates how epidemiologic risk translates into clinical prevention policy via latent TB screening before TNF-α blockade.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
For current status tracking and priority setting, use "Global tuberculosis report 2025" (2025) and the associated summaries ("global-tb-report-2025_factsheet.pdf" (2025); "Tuberculosis: Global deaths decline for first time since pandemic" (2025)) to anchor burden (10.7 million ill; 1.23 million deaths in 2024) and trend comparisons (1% reduction from 2023). For implementation constraints and research planning, "GTBreport2024_top findings and messages_English" (2025) provides quantified funding levels and gaps (US$5.9 billion for services in 2024; US$1.2 billion for research in 2023), which can be used to motivate modeling and prioritization efforts aligned with burden metrics.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Global tuberculosis report (2014) | 2014 | — | 13.2K | ✕ |
| 2 | Deciphering the biology of Mycobacterium tuberculosis from the... | 1998 | Nature | 7.8K | ✓ |
| 3 | An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prev... | 2007 | American Journal of Re... | 5.9K | ✕ |
| 4 | Worldwide incidence and prevalence of inflammatory bowel disea... | 2017 | The Lancet | 5.6K | ✕ |
| 5 | Increasing Incidence and Prevalence of the Inflammatory Bowel ... | 2011 | Gastroenterology | 4.7K | ✕ |
| 6 | Drug repurposing: progress, challenges and recommendations | 2018 | Nature Reviews Drug Di... | 4.3K | ✕ |
| 7 | Tuberculosis Associated with Infliximab, a Tumor Necrosis Fact... | 2001 | New England Journal of... | 3.7K | ✓ |
| 8 | Global Burden of Tuberculosis | 1999 | JAMA | 3.0K | ✕ |
| 9 | Simultaneous detection and strain differentiation of Mycobacte... | 1997 | Journal of Clinical Mi... | 2.9K | ✓ |
| 10 | Genes required for mycobacterial growth defined by high densit... | 2003 | Molecular Microbiology | 2.6K | ✓ |
In the News
A New Era in Tuberculosis Prevention and Treatment: Breakthroughs in Drug Development and Future Prospects
|
Global Tuberculosis Report 2025
The WHO Global tuberculosis report 2025 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regio...
The impact of 2025 funding cuts on TB services
In 2025, decisions by the government of the United States of America (USG) and wider political developments have substantially changed the landscape of international donor funding, including for he...
Countries and donors must sustain investment in fight ...
TB. The recent US funding cuts have halted numerous clinical trials, setting back TB research and innovation, with many of them being critical for children with TB. This is a major step back in the...
Global gains in tuberculosis response endangered by ...
# Global gains in tuberculosis response endangered by funding challenges 12 November 2025 News release Reading time:
Code & Tools
## About Models for the Tuberculosis elimination framework Activity Custom properties ### Stars **1**\ star ### Watchers **0**\ watch...
{{ message }} @TB-Modeling # TB Modeling and Translational Epi Group Interdisciplinary group of faculty, fellows, and students with an interest i...
Examples of systems that have already been implemented in Starsim include sexually transmitted infections (HIV, HPV, and syphilis, including co-tra...
*epidemics*is an R package that provides modular representations of populations and public health response measures, allowing them to be combined w...
The package provides an efficient and very flexible framework to conduct data-driven epidemiological modeling in realistic large scale disease spre...
Recent Preprints
Global tuberculosis report 2025
The WHO Global tuberculosis report 2025 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regi...
Global Tuberculosis Report 2025
The WHO Global tuberculosis report 2025 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regio...
GTBreport2024_top findings and messages_English
has been stagnating. Funding for provision of TB prevention, diagnosis and treatment amounted to US$ 5.9 billion in 2024, and funding for TB research was US$ 1.2 billion in 2023.d These figures ...
global-tb-report-2025_factsheet.pdf
TUBERCULOSIS IS THE WORLD’S LEADING INFECTIOUS KILLER 1.23 MILLION TB DEATHS INCLUDING 150 000 IN 2024 AN ESTIMATED 10.7 MILLION PEOPLE FELL ILL WITH TB 83 MILLION DRUG-RESISTANT TB REMAINS A PUBLI...
Tuberculosis: Global deaths decline for first time since pandemic
WHO’s global tuberculosis report 20251 shows there were 10.7 million people with TB in 2024, a 1% reduction from 10.8 million in 2023, but still above the level of 2020 (10.3 million). Globally, th...
Latest Developments
Recent developments in tuberculosis research include significant progress toward developing effective and affordable treatments, as highlighted by a Lancet study from January 2026 (GHTC). Additionally, the WHO's 2025 Global Tuberculosis Report indicates that in 2024, TB incidence decreased slightly to 10.7 million cases, with ongoing efforts to address multidrug-resistant TB and improve treatment strategies (WHO). The 3rd Conference on Innovations in Tuberculosis scheduled for May 2026 aims to focus on new TB treatments and strategies (Academic Medical Education). Advances in drug development, including new drugs and regimens, continue to be a major focus, with organizations like TB Alliance working on faster, more effective cures (TB Alliance). In epidemiology, the latest WHO data shows a gradual decline in TB cases and deaths, but progress remains below targets set for 2025 and 2030, especially in high-burden countries (WHO).
Sources
Frequently Asked Questions
What is the difference between tuberculosis epidemiology and tuberculosis biology research?
Tuberculosis epidemiology quantifies disease frequency, distribution, and determinants in populations, as exemplified by Dye et al. (1999) in "Global Burden of Tuberculosis" estimating incident and prevalent TB and the proportion of smear-positive infectious pulmonary disease. Tuberculosis biology research focuses on organismal and host mechanisms, as exemplified by Cole et al. (1998) in "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" describing insights enabled by the complete genome sequence.
How is the global burden of tuberculosis measured in major surveillance syntheses?
Dye et al. (1999) in "Global Burden of Tuberculosis" reported surveillance-based estimates including 7.96 million new TB cases in 1997 (range 6.3–11.1 million) and 16.2 million existing cases (range 12.1–22.5 million). "Global tuberculosis report 2025" (2025) reported 10.7 million people fell ill with TB in 2024 and 1.23 million TB deaths in 2024, providing updated global burden benchmarks.
Which molecular methods support simultaneous detection and strain differentiation for TB diagnosis and epidemiology?
Kamerbeek et al. (1997) in "Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology" presented an approach intended to enable detection and strain differentiation without relying on technically demanding, culture-dependent RFLP workflows. The paper frames strain differentiation as essential for monitoring transmission in epidemiologic investigations.
How do genomic resources and functional genomics identify potential drug targets in Mycobacterium tuberculosis?
Cole et al. (1998) in "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" established a genome-wide foundation for studying M. tuberculosis biology. Sassetti et al. (2003) in "Genes required for mycobacterial growth defined by high density mutagenesis" identified genes required for mycobacterial growth, explicitly motivating target discovery for antimycobacterial drug design.
Why is latent TB screening emphasized for some immunomodulatory therapies?
Keane et al. (2001) in "Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent" concluded that active TB may develop soon after infliximab initiation and recommended screening for latent TB infection or disease before prescribing. This links TB epidemiologic risk to clinical prevention practices in patients receiving TNF-α–neutralizing agents.
What do recent WHO-linked reports say about TB trends and funding for services and research?
"Tuberculosis: Global deaths decline for first time since pandemic" (2025) reported 10.7 million people with TB in 2024, a 1% reduction from 10.8 million in 2023, and stated total TB deaths were 1.23 million in 2024. "GTBreport2024_top findings and messages_English" (2025) reported TB prevention/diagnosis/treatment funding of US$5.9 billion in 2024 and TB research funding of US$1.2 billion in 2023, described as 27% and 24% of the global targets (US$22 billion and US$5 billion annually by 2027).
Open Research Questions
- ? Which genes identified as essential in "Genes required for mycobacterial growth defined by high density mutagenesis" (2003) are most predictive of in vivo vulnerability and treatment-shortening potential when prioritized as drug targets?
- ? How can strain differentiation approaches described in "Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology" (1997) be integrated with contemporary surveillance reporting needs reflected in "Global tuberculosis report 2025" (2025) to improve attribution of transmission versus reactivation?
- ? Which genome-derived biological insights from "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" (1998) best explain heterogeneity in infectiousness implied by the smear-positive fraction reported in "Global Burden of Tuberculosis" (1999)?
- ? What screening and preventive strategies most effectively reduce iatrogenic TB risk in patients receiving TNF-α inhibitors, given the clinical warning and recommendation in "Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent" (2001)?
- ? How should limited financing quantified in "GTBreport2024_top findings and messages_English" (2025) be allocated across diagnostics, treatment, prevention, and research to maximize reductions in burden metrics reported in "Global tuberculosis report 2025" (2025)?
Recent Trends
Recent WHO-linked reporting in "Global tuberculosis report 2025" and "Tuberculosis: Global deaths decline for first time since pandemic" (2025) emphasized updated global burden estimates of 10.7 million people falling ill with TB in 2024 and 1.23 million TB deaths in 2024, including a stated 1% reduction in illness from 10.8 million in 2023.
2025Financing constraints were quantified in "GTBreport2024_top findings and messages_English" , which reported US$5.9 billion in 2024 for TB prevention/diagnosis/treatment and US$1.2 billion in 2023 for TB research, described as 27% and 24% of global targets (US$22 billion and US$5 billion annually by 2027).
2025Together, these reports shift near-term research and policy attention toward linking measurable epidemiologic progress to operational capacity for service delivery and sustained research investment, while older high-citation foundations (Kamerbeek et al. ; Cole et al. (1998); Sassetti et al. (2003); Keane et al. (2001); Dye et al. (1999)) remain central methodological and mechanistic reference points.
1997Research Tuberculosis Research and Epidemiology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tuberculosis Research and Epidemiology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers